India-made Covid-19 Vaccine Covaxin Now On UK's Approved Travel List

Bharat Biotech manufactured Covaxin, one of the vaccines being administered in India to protect against COVID-19, is on the UK's list of approved COVID-19 vaccines for international travellers from Monday.

It will benefit more fully vaccinated Indians planning travel to the UK without the need for a pre-departure PCR test or self-isolation at the address declared on their compulsory Passenger Locator Forms.

Like other fully vaccinated travellers, including those vaccinated with Covishield, they are required to pre-book a PCR or Lateral Flow Test on arrival in England, to be taken before the end of day 2.

"From 4am on Monday 22 November, the government will recognise vaccines on the World Health Organisation's Emergency Use Listing (WHO EUL) at the border," the UK's Department for Transport (DfT) confirmed.

"As a result, Sinovac, Sinopharm Beijing and Covaxin will be added to our existing list of approved vaccine for inbound travel, benefitting more fully vaccinated passengers, it said.

Earlier this month, the Bharat Biotech manufactured Covaxin - the second most used formulation in India - had received its WHO EUL status, resulting in the UK announcing plans to include it on its list of approved COVID vaccines from November 22.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor